Who can use Mounjaro: UK eligibility, BMI thresholds and what to expect

Step 1, Start with the BMI thresholds, then look beyond them

The licensed starting point is a BMI of 30 or higher. That threshold drops to 27 if you have at least one weight-related comorbidity, conditions that count include type 2 diabetes, prediabetes, hypertension, dyslipidaemia, obstructive sleep apnoea and osteoarthritis. These aren't arbitrary lines; they reflect where the clinical trial evidence, reviewed by the MHRA before licensing, showed meaningful benefit.

For some ethnic backgrounds (including South Asian, Chinese, Middle Eastern, Black African and African-Caribbean) UK guidance recognises that health risks associated with weight occur at lower body-mass indices. The qualifying thresholds shift down by 2.5 kg/m² accordingly, so 27.5 instead of 30, or 24.5 instead of 27 with a comorbidity. The Mounjaro eligibility overview covers these adjustments alongside the standard criteria.

Worth checking: BMI is a starting filter, not the whole story. Two people with identical BMIs can have very different clinical profiles. A prescriber looks at your weight history, existing conditions, current medicines and other relevant factors before deciding whether Mounjaro is appropriate for you, and at what dose to begin.

Step 2, Confirm you meet the basic health requirements

A question our prescribers hear most weeks is whether a specific health condition automatically rules out Mounjaro. The honest answer is: it depends on the condition and its severity.

Mounjaro is not suitable for people under 18. It is not recommended during pregnancy, breastfeeding or if you are actively trying to conceive. A personal or family history of medullary thyroid carcinoma, or a diagnosis of Multiple Endocrine Neoplasia type 2 (MEN2), is a contraindication listed in the prescribing information. A history of acute pancreatitis requires careful discussion, as does any serious condition affecting the gastrointestinal tract.

Kidney function, liver health, and whether you are already taking other medicines that affect blood sugar all factor in. None of these are absolute barriers to a conversation, they are reasons why the assessment has to be individual. The NHS patient information for tirzepatide covers contraindications and cautions in plain language, and our prescribers use exactly this framework when reviewing consultations.

Step 3, Understand the difference between private eligibility and NHS access

If you've looked into this already, you may have noticed two separate conversations happening: private licensed eligibility and NHS commissioning criteria. They are not the same thing.

Private eligibility follows the licensed indications described above, BMI 30 (or 27 with a comorbidity), adult, medically suitable. The NHS has a phased rollout with narrower criteria: initially restricted to people with a BMI of 40 or above plus four or more of five specified conditions (high blood pressure, dyslipidaemia, sleep apnoea, cardiovascular disease, type 2 diabetes), with subsequent cohorts broadening access gradually from June 2026 onwards. NICE's appraisal of tirzepatide (TA1026) sets out the NHS criteria and timetable in full.

Many people who meet the licensed eligibility for private treatment do not yet meet NHS thresholds, or do meet them but face a waiting list. A private route through a regulated pharmacy involves a clinical assessment just as thorough, because the safety requirements are the same regardless of who pays. You can read more about whether Mounjaro is right for your situation if you're weighing up the options.

What happens after eligibility is confirmed

Once a prescriber is satisfied that Mounjaro is clinically appropriate, treatment begins at the 2.5 mg dose, a starter intended to let your system settle before the dose is reviewed. Titration through the available strengths happens over subsequent weeks, paced by how well you are tolerating the medicine. You can explore how the practical process of getting Mounjaro works as a private patient, including what verification is involved.

At nume, every consultation is read and assessed by a GPhC-registered Independent Prescriber on the day it arrives, a real clinician making a clinical judgement, not automated scoring. If approved as suitable, your treatment is dispatched the same day for free next-working-day delivery. If Mounjaro is not right for you, we will tell you clearly why, and what the alternatives might be. The Mounjaro treatment page has full information on what is included in the service.

Cost is a practical consideration too. If you want to understand what private treatment involves financially, the Mounjaro pricing page explains what a transparent single price covers. Ready to find out where you stand? Check your eligibility with a free consultation, there is no obligation, and the assessment itself costs nothing.